Search results for " INESNET"

showing 1 items of 1 documents

Beliefs and preferences regarding biological treatments for severe asthma

2020

Background: Severe asthma is a serious condition with a significant burden on patients' morbidity, mortality, and quality of life. Some biological therapies targeting the IgE and interleukin-5 (IL5) mediated pathways are now available. Due to the lack of direct comparison studies, the choice of which medication to use varies. We aimed to explore the beliefs and practices in the use of biological therapies in severe asthma, hypothesizing that differences will occur depending on the prescribers’ specialty and experience. Methods: We conducted an online survey composed of 35 questions in English. The survey was circulated via the INterasma Scientific Network (INESNET) platform as well as throu…

Severe asthmaBehavior; Belief; Biological drug; Severe asthmainterleukine 5 IgEMULTICENTERDiseaseOmalizumabADD-ON THERAPYBehavior Belief Biological drug Severe asthmaDOUBLE-BLIND0302 clinical medicineMedicine and Health SciencesImmunology and AllergyEosinophil IL5 [Eos]030223 otorhinolaryngologyPulmonologistssevere asthma biological drug belief behavior3. Good healthBeliefSAFETYmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyEos: Eosinophil IL5ImmunologyBiological drugSpecialtylong-acting beta2-agonist OMASocio-culturaleSettore MED/10 - Malattie Dell'Apparato RespiratorioArticle03 medical and health sciencesQuality of life (healthcare)Omalizumab. OMA/IL5 Omalizumab plus anti-IL5 moleculeOMALIZUMABmedicineIntensive care medicineAsthmaBehaviorINterasma Scientific Network LABAbusiness.industryMEPOLIZUMABmedicine.diseaseEFFICACYICS inhaled corticosteroidsLIFE030228 respiratory systemImmunoglobulin E INESNETAllergistslcsh:RC581-607businessMepolizumab
researchProduct